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1. INTRODUCTION
Depression is the leading cause of disability1 and affecting about 121 million
people world wide. Depression can lead to suicide, a tragic fatality associated with the
loss of about 850000 lives every year. According to World Health Organization, by
the year 2020, depression is projected to reach 2nd place of the ranking of Disability
Adjusted Life Year (DALY) calculated for all ages, both sexes. Today depression is
already the 2nd cause  of  DALYs  in  the  age  category  15-44  years  for  both  sexes
combined.
1.1 DEPRESSION
Depression2 is  the  most  common  of  the  affective  disorders  defined  as
disorders of mood rather than disturbances of thought or cognition. It may range from
a very mild condition, bordering on normality to severe (psychotic) depression
accompanied by hallucination and delusions.
The most common mood disorders are major depression (unipolar depression)
and manic depression (bipolar depression). Major depression is the most common
psychiatric disorder that continues to result in considerable mortality and morbidity
despite their major advances in treatment. The life time prevalence is estimated to be
about 15%. It is twice as common in women than men.
Clinical depression3 may be related to an imbalance in endogeneous amines 5-
hydroxy tryptamine (5-HT) or norepinephrine (NE) in CNS led to an amine
hypothesis of etiology and spurred efforts to enhance synaptic action of these amines.
Most of the antidepressants primarily enhance the action of endogeneous amine
neurotransmitters, they act directly, not binding to 5-HT or NE receptors but
enhancing neurotransmitter action by inhibiting amine metabolism or removing
neurotransmitter from synapses. Increased synaptic 5-HT or NE level then counteract
the abnormally low level that produce depression.
a.  Symptoms
The most common symptoms4 of depression are the following
Introduction
2
-depressed mood most of the day
-loss of interest in pleasurable activities
-decreased or increased appetite
-weight loss or gain
-difficulty concentrating
-insomnia or hypersomnia
-feeling of worthlessness or guilt
-psychomotor retardation or agitation fatigue
-recurrent thought of death, suicide and or a suicide attempt.
b. Causes
There  are  a  number  of  factors  that  may  increase  the  chance  of  depression
including the     following:
Abuse: Past physical, sexual, or emotional abuse can cause depression later in life.
Certain medications: For example, some drugs used to treat high blood pressure,
such as beta-blockers or reserpine, can increase your risk of depression.
Conflict: Depression  may  result  from  personal  conflicts  or  disputes  with  family
members or friends.
Death or a loss: Sadness  or  grief  from  the  death  or  loss  of  a  loved  one,  though
natural, can also increase the risk of depression.
Genetics: A family history of depression may increase the risk. It's thought that
depression is passed genetically from one generation to the next. The exact way this
happens, though, is not known.
Major events: Even good events such as starting a new job, graduating, or getting
married can lead to depression. So can moving, losing a job or income, getting
divorced, or retiring.
Other personal problems: Problems such as social isolation due to other mental
illnesses or being cast out of a family or social group can lead to depression.
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Serious illnesses: Sometimes depression co-exists with a major illness or is a reaction
to the illness.
Substance abuse: Nearly 30% of people with substance abuse problems also have
major or clinical depression.
c. Theory of depression (The monoamone theory)
The main biochemical theory of depression is the monoamine hypothesis,
proposed by Schildkraut in 1965, which states that depression is caused by a
functional deficit of monoamine transmitters at certain  sites in the brain, while mania
results from a    functional excess. Initially, the hypothesis was formulated in terms of
noradrenaline (norepinephrine), but the subsequent work showed that most of the
observations were equally consistent with 5-hydroxytryptamine (5-HT) being the key
mediator. Attempts to obtain more direct evidence, by studying monoamine
metabolism in depressed patients or by measuring changes in the number of
monoamine receptors in post-mortem brain tissue, have tended to give inconsistent
and equivocal results and the interpretation of these studies is often problematic,
because the changes described are not specific to depression. Many studies have
sought to the amine hypothesis by looking for biochemical abnormalities in
cerebrospinal fluid, blood or urine or in post-mortem brain tissue, from depressed or
manic patients. They have included the studies of monoamine metabolites, receptors,
enzymes and transporters, largely with negative results. The major metabolites of
noradrenaline and 5-HT respectively are 3-methoxy-4-hydroxyphenylglycol (MHPG)
and 5-hydroxyindoleaceticacid (5-HIAA). These appear in the cerebrospinal fluid,
blood and urine.
Various attempts have been made to test for a functional deficit of monoamine
pathways in depression. Hypothalamic neurons controlling pituitary function receive
noradrenergic  and  5-HT  inputs,  which  control  the  discharge  of  these  cells.
Hypothalamic cells release corticotrophin-releasing hormone (CRH), which
stimulates pituitary cells to secrete adrenocorticotrophic hormone (ACTH), leading in
turn to cortisol secretion. The plasma cortisol concentration usually high in depressed
patients. CRH concentration in the brain and cerebrospinal fluid of depressed patients
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are increased. Therefore CRH hyperfunction as well as monoamine hypofunction,
may be associated with depression.
d. Treatment of depression
The three most commonly indicated treatments for depression are
psychotherapy, psychiatric medication, and (in severe cases) electroconvulsive
therapy. Psychiatric medication is the primary therapy for major depression. An
antidepressant is a pshchiatric medication used to alleviate mood disorders such as
major depression and dysthymia and anxiety disorders. Various antidepressants are
monoamine oxidase inhibitor (MAOs)selective serotonin reuptake inhibitor (SSRIs),
serotonin-norepinephrine inhibitor (SNRIs), norepinephrine reuptake inhibitor
(NRIs), norepinephrine-dopamine reuptake inhibitor (NDRIs), serotonin reuptake
transporter inhibitor (SERT). Recent studies suggest that combination therapy, a
Dopamine transporter inhibitor (DAT) and an SSRI or SNRI offers improved efficacy
in the treatment of depression.
In an effort to expand beyond classical monoamine based strategies, recent
medication development activities have focused on neurotropic factors, glutamatergic
system and hypothalamic pituitary axis as well as number of other well characterized
novel targets.
1.2.  MEDICINAL CHEMISTRY
The discipline of medicinal chemistry5 is devoted to the discovery and
development of new agents for treating diseases. Most of this activity is directed to
new natural or synthetic organic compounds. Medicinal chemistry was defined by
IUPAC specified commission as “it concerns the discovery, the development, the
identification and interpretation of the mode of action of biologically active
compounds at the molecular level”.
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The medicinal chemistry covers the following stages
? In the first stage new active substances or drugs are identified and prepared
from natural sources, organic chemical reactions or biotechnological
processes. They are known as lead molecules.
? The second stage is optimization of lead structure to improve potency,
selectivity and to reduce toxicity
? Third stage is development stage, which involves optimization of synthetic
route for bulk production and modification of pharmacokinetic and
pharmaceutical properties of active substances to render it clinically useful.
The focus on development of new synthetic drug compounds has resulted in
the incorporation of many other disciplines such as biochemistry and molecular
biology into medicinal chemistry.
1.3 HETEROCYCLIC COMPOUNDS
The organic compounds have an enormous diversity of structure. Many of
these structures contain ring systems. If the ring system is made up of atoms of carbon
and atleast one other element, the compound can be classed as heterocyclic. The
element that occur most commonly together with carbon in ring systems are nitrogen,
oxygen and sulphur.
a) Therapeutic uses of heterocyclic compounds
Heterocyclic compounds used as pharmaceuticals, as agrochemicals and as
veterinary products. They are used as optical brightening agents, as antoxidants, as
corrosion inhibitors and as additives with a variety of other functions. Many dyestuffs
and pigments have heterocyclic structures.
b)  Reasons for wide spread uses of heterocyclic compounds
? Their structures can be subtly manipulated to achieve a required modification
in function.
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? It is possible to incorporate functional groups either as substituents or as part
of the ring system itself.
? As intermediate in organic synthesis.
? Widely distributed in nature, importance to living systems and a key
component in biological processes.
? Many of the pharmaceuticals and most of other heterocyclic compounds with
practical application are not extracted from natural sources but are
manufactured.
1.4  PYRIMIDINE
Pyrimidine6 is a heterocyclic aromatic organic compound in which the two
nitrogen atoms have the same positional relationship to each other as in amidines and
in the imidazoles. It occur in many compounds vital to living systems. A substantial
number of synthetic pyrimidines are valuable chemotherapeutic agents. Pyrimidines
are important group of compounds since it occurs in purines, nucleic acids and
synthetic barbiturates. The pyrimidines uracil, thymine and cytosine occur very
widely  in  nature  since  they  are  components  of  nucleic  acids  in  the  form  of  N-
substituted sugar derivatives (nucleosides).
N
N
H
ONH2
NH
N
H
OO
NH
N
H
OO
CH3
Cytosine                               Thymine Uracil
a. Chemical properties
? . Water soluble hygroscopic compound, melting point 22°C
? Pyrimidines can be considered best as derivatives of pyridine and to a lesser
extent as cyclic amidines
? Much weaker base than pyridine, imidazole, amidine
? Only one of the nitrogen atom is alkylated
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? As the number  of nitrogen atoms in the ring increases the ring pi electrons
become less energetic and electrophillic substitution gets more difficult while
nucleophillic substitution gets easier
? Reduction in resonance stabilization of pyrimidines may lead to addition and
ring cleavage reactions rather than substitutions. This manifestation is
observed in Dimroth rearrangement
b.  Synthesis of pyrimidines
The most general and widely used route to pyrimidines involves the
combination  of  reagent  containing  the  N-C-N  skeleton  with  one  containing  C-C-C
unit. Urea, thiourea and guanidine are commonly used as N-C-N
reagents(nucleophiles) and ???-unsaturated ketones or acid derivatives as C-C-C
fragments. Synthesis can be readily achieved by reaction is carriedout in  HCl or
sodiumethoxide in ethanol under reflux.
A method that is closely related to general route to pyrimidine is the Biginelli
dihydropyrimidine synthesis. In its classical form it is a three component
condensation of a ?-ketoester, an aromatic aldehyde and urea. This method becomes a
variant of the standard approach to pyrimidines.
CH3
EtO
O
O
ArCHO
CH3
EtO
O
O
AR
(NH2)2CO NH
N
H
O
EtO
CH3 O
AR
Nowadays, Multicomponent reactions are of increasing importance in organic
and medicinal chemistry. In times where a premium is put on speed, diversity and
efficiency in drug discovery process, MCR strategies offer significant advantages
over conventional linear type synthesis. The Biginelli three component protocol is
particularly attractive since the resulting dihydropyrimidone (DHPM) scaffold
displays a wide range of biological activities, which has led to the development of a
number of lead compounds based on that structural core. Although a large number of
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functionalized DHPMs can be potentially be prepared and the synthesized
heterocyclic scaffold remains a structurally relatively simple dihydropyrimidone
derivative.
In  classical  Biginelli  approach,  we  have  considered  the  use  of  4-
chloroacetoacetate building block in Biginelli type condensation. The resulting
functionalized DHPM appeared to be an ideal chemical template for the generation of
a interesting bicyclic scaffold pyrrolo[3,4-d]pyrimines. The present study describe the
synthesis of heterobicyclic scaffold from common chemical template employing
conventional method.
c. Biological importance of pyrimidines7
The pyrimidine skeleton is of great importance as it is available in a large
variety of naturally occurring compounds and also in clinically useful molecules
having diverse biological activities. Because of their involvement as bases in DNA
and RNA, they become very important in the world of synthetic chemistry.  They
include anticancer, antiviral, antibacterial, anti-inflammatory, cardiovascular,
antiepileptic, antifungal activities.
The following are some important biological and medicinal compounds
possess substituted pyrimidine nucleus
Flucytosine
N
H
N
NH2
F
O
Category: antifungal
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Minoxidil
N
NN NH
OH
NH2
Category: potassium channel opener (vasodilator)
Barbitone
NH
N
H
O
O
O
Category: Hypnotic, Sedative and Anticonvulsant
2-Thiouracil
N
H
NH
O
S
Category: Antithyroid
Monastrol
NH
N
H
CH3
EtOOC
S
OH
Category: Mitotic kinesin Eg5 inhibitor
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Batzelladine B
NHN
(CH2)6
O N
+
N
H
N
H
(CH2)6
CH3
O O(CH2)2NH
O
CH3
NH
NH2
NH2
+
Category: Inhibitor of HIV envelope protein gp-120
Tegafur
NH
N
O
F
O
O
Category: Antineoplastic
Amicetin
N
N NH
O
O
CH3
O
OH
OH
OH O
Category: Antibiotic
Buspirone
N
O
O
(CH2)2
N N
N
N
Category: 5-HT1A antagonist, Anxiolytic, Antidepressant.
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Stauvidine
N
NH
O
O
CH3
O
Category: Anti HIV
Above information clearly explains the need of an ideal antidepressant agents
in treating the patients with depression.
Though there are wide range of antidepressant agents available for clinical
use, a novel approach to identify a series of antidepressant agents was inspired by the
fact of limited exploitation of fused pyrimidine derivatives in this segment. Pyrrole
and its analogues exhibiting various pharmacological activities such as antimicrobial,
analgesic. Similarly pyrimidine and its derivatives exhibiting diverse pharmacological
activities such as anticancer, antiviral, antimicrobial activities. Though pyrimidine
and analogues have known pharmacological activities, surprisingly pyrimidine
derivatives were not much evaluated for their antidepressant activities. Hence, the
above discussed information about both pyrimidine and pyrrole motivated towards
synthesizing a novel series of pyrimidine fused with pyrrole.
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2. REVIEW OF LITERATURE
Antidepressant is a psychiatric medication used to alleviate mood disorders
such as major depression, dysthymia and anxiety disorder. Many drugs produce an
antidepressant effect but restriction on their use. Our current understanding of its
pathogenesis is limited and existing treatments are inadequate. The present review of
literature suggest that the heterocyclic moieties and their derivatives showing
antidepressant activity.
Pei-Pei Kung., et al8., (2011) studied the optimization of potent, selective and orally
bioavailable Pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90.
Identification of development candidate 2-Amino-4-{4-chloro-2-[2-(4-fluoro-1H-
pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-
pyrrolo[3,4-d]pyrimidine-6-carboxamide.
N
N
N
NH
F
F
F
NH2
O
O
Cl Cl
N
N
F
Kim JY., et al9., (2010) reported the arylpiperazine-containing pyrimidine 4-
carboxamide derivatives targeting serotonin 5-HT2A, 5-HT2C and  the  serotonin
transporter as a potential antidepressant.
N
N
NH
O
N N
S
CH3
CH3
CH3
CH3
Review of Literature
13
Kang., et al10., (2010) reported that the aryl piperazine containing pyrrole-3-
carboxamide derivatives targeting serotonin 5-HT2A, 5-HT2C and  the  serotonin
transporter as a potential antidepressant.
N
NNH
ON
CH3
R
R'
R"
R’ & R” = Cl , R = Me
Lucas., et al11., (2010) synthesized a new series of monoamine triple uptake
inhibitors through scaffold homologation of recently reported series of 3,3-
disubstituted pyrrolidine TRIS.
N
H
R1
R2
N
H
R2 O
N
R1
R1 = H , R2 = C6H5CH2CH3
Herhold F., et al12., (2009) reported the novel 4-aryl-pyrido[1,2-c]pyrimidines with
dual SSRI and 5-HT1A activity.
N
N O
O
N
N
H
R1R2
R3
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R1 =OCH3 , R2& R3 =H
R1 = F , R2 = H , R3 = OCH3
R1& R3 = H , R2 = CH3
R1 = F , R2& R3= H
Su-Ying Wu., et al13., (2008) reported the identification, SAR exploration and
molecular modeling of 6,7-dihydro-4H-pyrazolo-[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-
dione scaffold as aurora kinase A inhibitors.
N
N
N
N
O
O
R2
R3
N
N
H
N
N
O
O
R1
O
Bannwart et al14., (2008) designed a novel 3,3-disubstituted pyrrolidines as selective
triple serotonin, norepinephrine, dopamine reuptake inhibitors.
N
H
AR
AR = 5-indaonyl
Zajdel et al15., (2007) synthesized a novel class of aryl piperazine containing N-
acylated aminoacids:Their synthesis, 5HT1A, 5-HT2A receptor affinity and invivo
pharmacological evaluation.
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N
O
ONH
R
O
N
N
R'
R=admantyl, R’ =3-Cl
R=C2H4 , R’= 2-OCH3
R=C6H11,R’=2-OCH3
Rodrigues ALS., et al16., (2005) reported the antidepressant-like antinociceptive-like
action of 4-(4 ' -cholorophenyl)-6-(4"-methylphenyl)-2-hydrazinepyrimidine Mannich
base in mice.
NN
Cl CH3
NH
NH2
Darias V., et al17., (1999) studied the antidepressant activity of 4-phenyl-2-thioxo-
benzo[4,5]thieno[2,3-d]pyrimidine derivatives.
Zelle et al18., (1994) carried out the synthesis and pharmacological characterization of
ABT:200:A putative novel antidepressant combining potent ?2 antagonism  with
moderate NE uptake inhibition.
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OO
N
Bernier JL., et al19., (1980) reported the synthesis and structure-activity relationship
of a pyrimido[4,5-d]pyrimidine derivative with antidepressant activity.
To generate, a new  antidepressant agent, the heterobicyclic scaffold
pyrrolo[3,4-d] pyrimidinone derivatives have been selected for synthesis. Synthesis of
the above said  scaffold carried out by multicomponent reaction followed by
cyclization. The following literatures have been  reviewed based on synthesis.
Ujwala B.Belge., et al20., (2011) synthesised and evaluated the preliminary
pharmacological screening of 4-aryl substituted-3,4-dihydropyrimidin-
2(1H)one/thione derivatives as calcium channel blockers.
OH
+ NH2NH2
X
+ CH3 OR'
O O HCl
Ethanol
R NH
N
H
XCH3
O
EtO
R
R=4-N02 , 4-OH, 4-CH3, 4-Br
Rajasekaran S., et al21., (2011) carried out the design, synthesis and biological
activity of substituted dihydropyrimidin-2-(1H)-thiones.
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OH
+ CH3 OEt
O O
+ NH2NH2
S
NH
N
H
O
EtO
SCH3
NH
ClO
NH
NCH3
O
EtO
S
NH
O
R
1
2
1.ethanol/HCl  2.pyridine
R=H, 2-CH3, 4-CH3, 4-Cl, 3-NO2
Shah T.B., et al22., (2010) conducted the synthesis and invitro study of biological
activity of heterocyclic N-Manich bases of 3,4-dihydropyrimidin-2(1H)-thiones.
R 3
CHO
R 2
R 1
+ CH 3 OEt
O O
+ N H 2NH 2
S
1 a-d
2 3
MeOH, HCl
R 3
R 2
R 1
N H
N
H
O
EtO
CH 3 S
4 a-d
HCHO
R 3
R 2
R 1
N
N
O
EtO
CH 3 S
R
R
sec amine
5 a-g
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4a-d : R1=R2=R3=H 5a-g: R=benzimidazole, benztriazole
R1=OH, R2&R3=H phthalimide, 2-ph bezimidazole
R1=H,R2=OMe,R3=OH 2-Me benzimidazole,morpholine
R1&R2=H,R3=OMe tetrahydrocarbazole
Mithun Ashok., et al23., (2007) carried out the convenient one pot synthesis of some
novel derivatives of thiazolo[2,3-b]dihydropyrimidinone possessing 4-
methylthiophenyl moiety and evaluation of their antibacterial and antifungal
activities.
Selma Sarac., et al24., (2006) conducted the synthesis of 4-aryl-3,4-dihydropyrimidin
-2(1H)-thione derivatives as potential calcium channel blockers.
Abdel Momen A EI Khamry., et al25., (2006) demonstrated the synthesis of 4-aryl-
isoxazolo[5,4-d]pyrimidin-6-one(thione) and 4-aryl-pyrazolo-[3,4-d]-pyrimidin-6-one
derivatives of potential antihypertensive activity.
Oliver Kappe. C., et al26., (2002) conducted the traceless solid-phase synthesis of
bicyclic dihydropyrimidones using multidirectional cyclization cleavage.
O
EtO2C
CH3
+
H
R1
O
+ NH2NH2
O
H+ NH
N
H
CH3
EtO2C
O
R1
NH
N
H
O
R1
O
O
NH
N
H
N
R1
O
O
R2
NH
N
H
R1
O
NH
N
R3
O
Heat
R2NH2
R3 NHNH2
Mirzaei. Y.R., et al27., (2001) investigated the chemical reactivity of positions N-3,
C-5 and C6-methyl group in biginelli type compounds and synthesis of new
dihydropyrimidine derivatives.
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Tarzia.G., et al28.,(1979) performed the synthesis and anti-inflammatory properties of
some pyrrolo(1H,3H)[3,4-d]pyrimidin-2-ones and pyrrolo(1H,6H)[3,4-d]pyrimidin-2-
ones.
Philip L. Southwick., et al29., (1974) reported the synthesis of antifols related to 2,4-
diamino-6,7-dihydro-5H-pyrrolo[3,4-d] pyrimidine. Enhancement of antiparasitic
selectivity by nitrogen-linked mono- and dichlorobenzoyl groups or the 3,4–
dichlorophenylthiocarbamoyl group.
Tuvia Sheradsky., et al30., (1964) reported the 6,7-dihydro-5H-pyrrolo[3,4-
d]pyrimidines. Syntheses based on 3-amino- and 3-methoxy-1-acyl-4-cyano-3-
pyrrolines.
N
N
NH
NH2
R
Cavalla. J.F31., (1964) reported the 3-amino-4-cyano-3-pyrrolines: Their conversion
to pyrrolo[3,4-d]pyrimidines.
N
N
N
OH
OH
R
O
Philip L. Southwick., et al32., (1963) reported the compounds in the Pyrrolo[3,4-
d]pyrimidine series. Syntheses Based on 2,3-Dioxopyrrolidines.
From the exclusive literature survey conducted from the available sources, it is
clear that so far no derivatives of pyrimidine fused with pyrrole has been screened for
antidepressant activity.
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3. AIM AND OBJECTIVE
Depression affects up to 20% of population world wide and is the fourth
leading cause of disease or disability. Most antidepressants include delayed clinical
benefit, serious side effects and response in less than 50% of patients. Neither the
pathophysiology of depression nor the mechanism of action of various antidepressants
is fully understood. Consequently, there is still a greater need or fast acting, safer and
more effective treatments for depression. Hence the search for newer antidepressant
agents is made an attempt to synthesis a series of compounds.
Nitrogen containing heterocyclic compounds featured predominantly in early
studies of chemistry and they were closely associated with the development of
organic  chemistry.  Pyrimidines  are  the  most  important  one  among  them  because  of
their wide range of pharmacological uses. Pyrimidine fused with pyrrole derivatives
are synthesized and evaluated for antidepressant activity.
The main objective of the present study is the following:
1. Synthesis of new series of 2-thioxo-5H-pyrrolo[3,4-d]pyrimidin-5-one
derivatives
2. Characterization of the synthesized compounds by spectral methods
viz.infrared (IR Spectra), Nuclear magnetic resonance spectra (1H NMR) and
Mass spectra.
3. Evaluation of acute toxicity study.
4. Evaluation of antidepressant activity by behavioural despair test.
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4. MATERIALS AND METHODS
The methods employed in this research included the following:
1. Introduction
2. Synthesis
3. Characterization
4. Evaluation of biological activity
4.1  INTRODUCTION
One  of  the  things  that  makes  chemistry  unique  among  the  science  is
synthesis. Synthetic organic chemistry is focused largely on compounds of
pharmaceutical importance and covers novel molecule design, natural product
analogues and derivatives of natural products.
Lipinski Rule of Five
Christopher Lipinski's rule-of-five analysis helped to raise awareness about
properties and structural features that make molecules more or less drug-like. The
guidelines were quickly adopted by the pharmaceutical industry as it helped apply
ADME considerations early in preclinical development and could help avoid costly
late-stage preclinical and clinical failures. The guidelines predict that poor
absorption or permeation of a orally administered compound are more likely if the
compound meets the following criteria:
? Not more than 5 hydrogen bond donors (nitrogen or oxygen atoms with
one or more hydrogen atoms).
? Not more than 10 hydrogen bond acceptors (nitrogen or oxygen atoms).
? A molecular mass not greater than 500 daltons.
? An octanol-water partition coefficient log P not greater than 5.
? No of rotatable bonds ? 10.
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The physical properties of the synthesized molecules were calculated using a
Software called Molinspiration on line database. The values are given in Table 1
Lipinski rule of the synthesized compounds
Table 1. Lipinski rule of synthesized compounds.
S.No miLogP M.Wt nON nOHNH n rot b TPSA Molarvolume n violation
IIa 1.635 315.39 5 3 4 64.59 276.87 0
IIb 0.878 289.36 5 3 3 64.59 249.46 0
IIc 0.98 332.42 6 3 4 67.82 295.36 0
IId 1.556 323.80 5 3 3 64.59 262.99 0
IIe 0.819 305.35 6 4 3 84.81 257.47 0
IIf 0.525 349.41 7 3 5 83.05 300.55 0
IIg 0.217 335.38 7 4 4 94.05 283.02 0
miLogP - LogP
M.Wt - Molecular weight
 nON - No of hydrogen bond acceptor
 nOHNH - No of hydrogen bond donar
 n rot b - No of rotatable bonds
 TPSA - Total polar surface area
From the above data, the synthesized compounds have satisfied the Lipinski
rule of Five.
4.2 SYNTHESIS
The synthesis of pyrrolo[3,4-d]pyrimidine33,34 involves both pyrimidine and
pyrrole precursors almost evenly. The presence of a carboxylic ester at position 5 of
a pyrimidine ring  contributes to a series of fused pyrroles containing a carbonyl
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group. The pyrimidine containing a carboxylic ester at position 5 is heated at reflux
conditions with primary amine providing pyrrolo[3,4-d]pyrimidine.
Step 1:
The synthesis is based on “Biginelli dihydropyrimidine synthesis” which
involves acid catalyzed three component cyclocondensation of ?-ketoester, an
aromatic aldehydes and urea or thiourea.
Reaction mechanism:
The first mechanism for the synthesis of dihydropyrimidine (Biginelli
reaction) were conducted by Folkers and Johnson in 1933. In 1973, a second
mechanistic proposal was suggested by Sweet and Fissekis. In 1997, the mechanism
was provided by Kappe whose proposal is currently the accepted mechanism for the
Biginelli reaction.
Kappe35(1997)
+
NH2 NH2
O
Ph H
O Ph
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O
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H
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Step 2:
6-Chloromethyl functionalised dihydropyrimidine intermediates on
treatment with an excess of primary amine in methanol provided the pyrrolo[3,4-
d]pyrimidine. The corresponding amine was allowed to react with the appropriate
chloromethyl dihydropyrimidine at ambient or at a slightly elevated temperature for
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1-2 hours followed by heating under reflux for 5-6 hours. The solid pyrrolo[3,4-
d]pyrimidine was directly precipitated from the solution upon cooling.
Reaction mechanism:
The reaction takesplace in two steps. In the first step, the chlorogroup was
displaced by excess amine nucleophile. In the second step, the cyclative
nucleophillic cleavage (Lactam formation) by cyclization of ethyl ester with the
resulting secondary amine. On the basis of different reactivity of the primary
amines, the nucleophillic displacement was carried out at room temperature for
alkylamines and phenylethylamines or at 50°C for benzylamines and sterically
hindered amines.
NH
N
H
O
EtO
Cl
S
R
2hrs stirring
R'-NH2
NH
N
H
O
EtO
NH
R' S
R
KOH/Methanol
NH
N
H
N
O
S
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R
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a.  Synthetic scheme
EtO
Cl
O
O
+ NH2NH2
S
+
H O
R
NH
N
H
O
EtO
Cl
S
R
ethanol
HCl
reflux 6 hrs
I a-g
                                                                                                         R’-NH2
                                                                                                Stirring 2 hrs
                                                                                            KOH/Methanol
                                                                                                Reflux 6 hrs
NH
N
H
N
S
O
R'
R
R = (i) -CH=CH- (ii) –H (iii) -N(CH3)2
(iv) -4-Cl   (v) -2-OH  (vi)-3,4-di-OCH3
(vii) -3-OCH3, -4-OH
 R’ = -CH2-CH2-OH
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b.  Reactant profile36
The  synthesis  was  carried  out  in  room  temperature.  Solvents  and  reagents
used were of laboratory grade. All the reactions were conducted in thoroughly dried
apparatus. The reactants and solvents used for the synthesis were given in Table 2.
Table 2. Reactant profile
Reagent Mol. Formula
Mol.
weight
Description mp
Ethyl-4-
chloroacetoacetate
C6H9ClO3 164.59 pale reddish-yellow
clear liquid
115°C
Thiourea CH4N2S 76.12 White solid 182°C
Benzaldehyde C7H60 106.12 Colourless liquid 178.1°C
Cinnamaldehyde C9H8O 132.15 Yellow oily liquid 252°C
P-dimethyl
aminobenzaldehyde
C9H11NO 149.19 yellowish solid 74°C
p-chloro benzaldehyde C7H5ClO 140.57 White crystalline
solid
46°C
Salicylaldehyde C7H6O2 122.13 pale yellow oily
liquid
97°C
Veratraldehyde C9H10O3 166.17 White to offwhite
crystalline fused
mass
43°C
Vanillin C8H8O3 152.15 White crystals with
floral pleasant odour
81°C
c. Synthetic procedure:
Step 1:
Synthesis of 6-chloromethyl derivative of dihydropyrimidine-2-thione (Ia-g):
A mixture of Ethyl-4-chloroacetoacetate (3.0mmol), appropriate aldehydes
(3.0mmol), thiourea (3.5mmol) were refluxed in 30ml ethanol containing 0.5ml
hydrochloric acid for 5-6 hrs. The reaction mixture was cooled and poured into ice-
cold water. The solid product which was obtained  was filtered, dried and
recrystallized from ethanol.
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Step 2:
Synthesis of 2-thioxo-5H-pyrrolo[3,4-d]pyrimidin-5-one (IIa-g):
To the product obtained in first step, solution of ethanolamine in methanol
was added  dropwise with stirring at 25-30°C. Stirring was continued for 1-2 hrs.
Then methanolic sodium hydroxide solution (5ml) was then added. The reaction
mixture was refluxed for 6 hrs and the excess of solvent was distilled.  The reaction
mixture was cooled to room temperature. The solid product which was obtained was
washed with cold methanol, dried and recrystallized from suitable solvent.
Recrystallization
All the synthesised compounds were purified by  recrystallization.
Recrystalization of the synthesised compounds were done using suitable solvents such
as acetone or ethanol.
Identification methods
The synthesised compounds were identified by following methods
Melting point
The melting points of the synthesised compounds were determined by open
capillary tube method and are presented uncorrected.
Thinlayer chromatography
Precoated silicagel GF plates were used as a stationary phase, benzene and
ethylacetate as mobile phase for the synthesised compounds. The spots were
identified by iodine vapour or UV chamber.
A  single  spot  with  no  secondary  spots  and  absence  of  spot  for  parent
compounds confirmed the purity of the compounds.
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d.  Product profile
The synthesized compounds and their structure are given below.
IIa
NH
N
H
N
OH
O
S
6-(2-hydroxyethyl)-4-[(E)-2-phenylethenyl]-2-thioxo-1,2,3,4,6,7-hexahydro-
5H-pyrrolo[3,4-d]pyrimidin-5-one.
IIb
NH
N
H
N
OH
O
S
6-(2-hydroxyethyl)-4-phenyl-2-thioxo-1,2,3,4,6,7-hexahydro-5H-pyrrolo[3,4-
d]pyrimidin-5-one
IIc
NH
N
H
N
OH
O
S
N
CH3CH3
4-[4-(dimethylamino)phenyl]-6-(2-hydroxyethyl)-2-thioxo-1,2,3,4,6,7-
hexahydro-5H-pyrrolo[3,4-d]pyrimidin-5-one
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IId
NH
N
H
N
OH
O
S
Cl
4-(4-chlorophenyl)-6-(2-hydroxyethyl)-2-thioxo-1,2,3,4,6,7-hexahydro-5H-
pyrrolo[3,4-d]pyrimidin-5-one
IIe
NH
N
H
N
OH
O
S
OH
6-(2-hydroxyethyl)-4-(2-hydroxyphenyl)-2-thioxo-1,2,3,4,6,7-hexahydro-5H-
pyrrolo[3,4-d]pyrimidin-5-one
IIf
NH
N
H
N
OH
O
S
O
CH3
O
CH3
4-(3,4-dimethoxyphenyl)-6-(2-hydroxyethyl)-2-thioxo-1,2,3,4,6,7-hexahydro-
5H-pyrrolo[3,4-d]pyrimidin-5-one
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IIg
NH
N
H
N
OH
O
S
OH
O
CH3
6-(2-hydroxyethyl)-4-(4-hydroxy-3-methoxyphenyl)-2-thioxo-1,2,3,4,6,7-
hexahydro-5H-pyrrolo[3,4-d]pyrimidin-5-one
4.3 CHARACTERIZATION37,38,39
The synthesised compounds were characterized by using the following
methods
IR Spectra
IR Spectra was recorded on ABB Spectrum spectrometer in the range of
4000-400cm-1 using KBr pellet technique and expressed in cm-1.
1H NMR Spectra
Proton  NMR  Spectra  was  recorded  on  BRUKER  Advance  500  NMR
Spectrometer using the solvent Deuterated Dimethyl sulphoxide. Chemical shifts are
reported in parts per million, relative to TMS as an internal standard.
Mass spectra
The Mass Spectra recorded on a JEOL GC Mate II Mass Spectrophotometer
operating as direct probe using Electron Ionization technique
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Table 3. Physical data of the synthesised compounds
S.No Description
Mol
formula
Mol
weight
Solubility
mp
(°C)
% Yield
IIa Brown  solid C16H17N3O2S 305.39 DMSO,
ethanol
118 66.67
IIb Yellow solid C14H15N3O2S 289.35 DMSO,
ethanol,
acetone
220 50.25
IIc Red solid C16H20N4O2S 332.42 DMSO,
ethanol,
acetone
120 47.72
IId Yellow solid C14H14ClN3O2S 323.79 DMSO,
ethanol,
acetone
210 67.4
IIe Yellow solid C14H15N3O3S 305.35 DMSO,
ethanol
235 56.09
IIf Yellow solid C16H19N3O4S 349.40 DMSO,
ethanol
157 54.11
IIg Brown solid C15H17N3O4S 335.37 DMSO,
ethanol
102 53.69
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Table 4. Spectral data of the synthesised compounds
S.No IR ? cm-1 (KBr) 1H NMR ? ppm Mass(m/zvalue)
IIa 3425(OH str)
2970(CH str
methylene)
2932(NH
str)1662(C=O str)
1450(C=C str
aromatic)
0.9-1.3(m,4H,CH2)
2.9(s,2H,CH2)5.2(s,1H,CH)
6.3(s,1H,CH) 6.7(s,1H,CH) 7.8(m,1H,OH)
8-8.5(m,5H,Ar-CH),9.5(s,1H,NH)
9.8(s,1H,NH)
315.24(M+ion
peak)
IIb 3317(OH
str)3202(NH str)
2854(CH str
methylene)2368(C=S
str)
1520(C=O
str)1450(C=C str
aromatic)
0.9-
1.3(m,4H,CH2)2.9(s,2H,CH2)4.0(s,1H,CH)
7.7(m,1H,OH)7.8-
8.5(m,5H,ArCH)9.6(s,1H,NH)
9.8(s,1H,NH)
289.54(M+ion
peak)
IIc 3317(OH
str)3194(NH str)
2924(CH str
aromatic)1065(C=O
str)
1443(C=C str
aromatic)
0.8-
1.3(m,4H,CH2)2.9(s,1H,CH2)3.0(s,6H,CH3)
4.0(s,1H,CH)6.5-7.0(m,4H,Ar-CH)
7.8(m,1H,OH)9.2(s,1H,NH)9.8(s,1H,NH)
332.03(M+ion
peak)
IId 3379(OH
str)2924(CH str
methylene)
2361(C=S
str)1589(C=0 str)
1489(C=C str
aromatic)
0.9-
1.3(m,4H,CH2)3.9(s,2H,CH2)4.1(s,1H,CH)
6.5-7.7(m,4H,Ar-CH)7.9(m,1H,OH)
8.3(s,1H,NH)9.2(s,1H,NH)
323.14(M+ion
peak)
IIe 3418(OH
str)2955(CH str
methylene)
2368(C=S
str)1566(C=O str)
1458(C=C str
aromatic)
1.4(m,2H,CH2)1.9(m,2H,CH2)2.6(s,2H,CH2)
3.8(s,1H,CH)5.1(s,1H,Ar-OH)
7.2-7.5(m,4H,Ar-CH)7.9(m,1H,OH)
8.5(s,1H,NH)9.2(s,1H,NH)
305.36(M+ion
peak)
IIf 3410(OH
str)2939(CH str
aromatic)
1636(C=O str)
1466(C=C str)
0.8-
1.2(m,4H,CH2)2.6(s,2H,CH2)2.9(s,6H,CH3)
4.2(s,1H,CH)6.7-7.2(m,3H,Ar-CH)
7.3(m,1H,OH)8.2(s,1H,NH)8.5(s,1H,NH)
349.25(M+ion
peak)
IIg 3418(OH str)
2932(CH str methyl)
1636(C=O str)
1381(C=C str
aromatic)
0.8-
1.2(m,4H,CH2)2.9(s,2H,CH2)3.2(s,3H,CH2)
4.1(s,1H,CH)5.3(s,1H,Ar-OH)
6.5-7.0(m,3H,Ar-CH)8.0(s,1H,NH)
9.2(s,1H,NH)
335.43(M+ion
peak)
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Spectroscopic study of synthesised compounds
Figure 1 shows the IR spectrum of compound IIa
 [6-(2-hydroxyethyl)-4-[(E)-2-phenylethenyl]-2-thioxo-1,2,3,4,6,7-hexahydro-
5H-pyrrolo[3,4-d]pyrimidin-5-one].
Fig. 1 3425(OH str), 2970(CH str methylene), 2932(NH str), 1662(C=O str),
1450(C=C str aromatic)
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Figure 2 shows the 1H NMR spectrum of compound IIa
[6-(2-hydroxyethyl)-4-[(E)-2-phenylethenyl]-2-thioxo-1,2,3,4,6,7-
hexahydro-5H-pyrrolo[3,4-d]pyrimidin-5-one].
Fig. 2 0.9-1.3(m,4H,CH2),  2.9(s,2H,CH2), 5.2(s,1H,CH), 6.3(s,1H,CH),
6.7(s,1H,CH) 7.8(m,1H,OH), 8-8.5(m,5H,Ar-CH), 9.5(s,1H,NH), 9.8(s,1H,NH).
Materials and Methods
 35
Figure 3 shows Mass spectrum of compound IIa
[6-(2-hydroxyethyl)-4-[(E)-2-phenylethenyl]-2-thioxo-1,2,3,4,6,7-
hexahydro-5H-pyrrolo[3,4-d]pyrimidin-5-one].
Fig 3 315.24 (M+), 237.21, 173.39, 63.7.
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Figure 4 shows IR spectrum of compound IIb
[6-(2-hydroxyethyl)-4-phenyl-2-thioxo-1,2,3,4,6,7-hexahydro-5H-pyrrolo[3,4-
d]pyrimidin-5-one].
Fig 4 3317(OH str), 3202(NH str), 2854(CH str methylene), 2368(C=S str),
1520(C=O str), 1450(C=C str aromatic)
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Figure 5 shows 1H NMR Spectrum of compound IIb
[6-(2-hydroxyethyl)-4-phenyl-2-thioxo-1,2,3,4,6,7-hexahydro-5H-pyrrolo[3,4
d]pyrimidin-5-one].
Fig 5 0.9-1.3(m,4H,CH2), 2.9(s,2H,CH2), 4.0(s,1H,CH), 7.7(m,1H,OH),
7.8- 8.5(m,5H,ArCH), 9.6(s,1H,NH), 9.8(s,1H,NH)
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Figure 6 shows Mass spectrum of compound IIb
 [6-(2-hydroxyethyl)-4-phenyl-2-thioxo-1,2,3,4,6,7-hexahydro-5H-
pyrrolo[3,4-d]pyrimidin-5-one]
Fig 6 289.54 (M+), 256.57, 149.32, 61.7.
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Figure 7 shows IR spectrum of compound IIc
 [4-[4-(dimethylamino)phenyl]-6-(2-hydroxyethyl)-2-thioxo-1,2,3,4,6,7-
hexahydro-5H-pyrrolo[3,4-d]pyrimidin-5-one].
Fig 7 3317(OH str), 3194(NH str), 2924(CH str aromatic), 1065(C=O str),
1443(C=C str aromatic)
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Figure 8 shows 1H NMR spectrum of compound IIc
       [4-[4-(dimethylamino)phenyl]-6-(2-hydroxyethyl)-2-thioxo-1,2,3,4,6,7-
hexahydro-5H- pyrrolo[3,4-d]pyrimidin-5-one].
Fig 8 0.8-1.3(m,4H,CH2), 2.9(s,1H,CH2), 3.0(s,6H,CH3), 4.0(s,1H,CH), 6.5-
7.0(m,4H,Ar-CH)7.8(m,1H,OH), 9.2(s,1H,NH), 9.8(s,1H,NH)
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Figure 9 shows Mass spectrum of compound IIc
[4-[4-(dimethylamino)phenyl]-6-(2-hydroxyethyl)-2-thioxo-1,2,3,4,6,7-
hexahydro-5H-pyrrolo[3,4-d]pyrimidin-5-one].
Fig 9  332.03(M+), 280.8, 119.31, 61.7.
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Figure 10 shows IR spectrum of compound IId
[4-(4-chlorophenyl)-6-(2-hydroxyethyl)-2-thioxo-1,2,3,4,6,7-hexahydro-5H-
pyrrolo[3,4-d]pyrimidin-5-one].
Fig 10 3379(OH str), 2924(CH str methylene), 2361(C=S str), 1589(C=0 str),
1489(C=C str aromatic)
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Figure 11 shows 1H NMR Spectrum of compound IId
[4-(4-chlorophenyl)-6-(2-hydroxyethyl)-2-thioxo-1,2,3,4,6,7-hexahydro-5H-
pyrrolo[3,4-d]pyrimidin-5-one].
Fig 11 0.9-1.3(m,4H,CH2), 3.9(s,2H,CH2), 4.1(s,1H,CH), 6.5-7.7(m,4H,Ar-
CH), 7.9(m,1H,OH), 8.3(s,1H,NH), 9.2(s,1H,NH)
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Figure 12 shows Mass spectrum of compound IId
[4-(4-chlorophenyl)-6-(2-hydroxyethyl)-2-thioxo-1,2,3,4,6,7-hexahydro-5H-
pyrrolo[3,4- d]pyrimidin-5-one].
Fig 12 323.14 (M+), 238.6, 125.39, 61.7
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Figure 13 shows IR spectrum of compound IIe
[6-(2-hydroxyethyl)-4-(2-hydroxyphenyl)-2-thioxo-1,2,3,4,6,7-hexahydro-5H-
pyrrolo[3,4-d]pyrimidin-5-one].
Fig 13 3418(OH str), 2955(CH str methylene), 2368(C=S str), 1566(C=O str),
1458(C=C str aromatic)
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Figure 14 shows 1H NMR spectrum of compound IIe
[6-(2-hydroxyethyl)-4-(2-hydroxyphenyl)-2-thioxo-1,2,3,4,6,7-hexahydro-5H-
pyrrolo[3,4-d]pyrimidin-5-one].
Fig 14 1.4(m,2H,CH2), 1.9(m,2H,CH2), 2.6(s,2H,CH2), 3.8(s,1H,CH),
5.1(s,1H,Ar-OH),  7.2-7.5(m,4H,Ar-CH), 7.9(m,1H,OH), 8.5(s,1H,NH),
9.2(s,1H,NH)
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Figure 15 shows Mass spectrum of compound IIe
[6-(2-hydroxyethyl)-4-(2-hydroxyphenyl)-2-thioxo-1,2,3,4,6,7-hexahydro-5H-
pyrrolo[3,4-d]pyrimidin-5-one].
Fig 15 305.3 (M+), 276.16, 218.68, 177.5, 61.7
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Figure 16 shows IR spectrum of compound IIf
[4-(3,4-dimethoxyphenyl)-6-(2-hydroxyethyl)-2-thioxo-1,2,3,4,6,7-
hexahydro-5H-pyrrolo[3,4-d]pyrimidin-5-one].
Fig 16 3410(OH str), 2939(CH str aromatic), 1636(C=O str), 1466(C=C str)
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Figure 17 shows 1H NMR spectrum of compound IIf
[4-(3,4-dimethoxyphenyl)-6-(2-hydroxyethyl)-2-thioxo-1,2,3,4,6,7-hexahydro-
5H-pyrrolo[3,4-d]pyrimidin-5-one].
Fig 17 0.8-1.2(m,4H,CH2), 2.6(s,2H,CH2), 2.9(s,6H,CH3), 4.2(s,1H,CH),
6.7-7.2(m,3H,Ar-CH), 7.3(m,1H,OH), 8.2(s,1H,NH), 8.5(s,1H,NH)
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Figure 18 shows  Mass spectrum of compound IIf
 [4-(3,4-dimethoxyphenyl)-6-(2-hydroxyethyl)-2-thioxo-1,2,3,4,6,7-
hexahydro-5H-pyrrolo[3,4-d]pyrimidin-5-one].
Fig 18 349.2(M+), 220.2, 150.3, 62.7.
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Figure 19 shows IR spectrum of compound IIg
[6-(2-hydroxyethyl)-4-(4-hydroxy-3-methoxyphenyl)-2-thioxo-1,2,3,4,6,7-
hexahydro-5H-pyrrolo[3,4-d]pyrimidin-5-one].
Fig 19 3418(OH str), 2932(CH str methyl), 1636(C=O str), 1381(C=C str
aromatic)
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Figure 20 shows 1H NMR spectrum of compound IIg
[6-(2-hydroxyethyl)-4-(4-hydroxy-3-methoxyphenyl)-2-thioxo-1,2,3,4,6,7-
hexahydro-5H-pyrrolo[3,4-d]pyrimidin-5-one].
Fig 20 0.8-1.2(m,4H,CH2), 2.9(s,2H,CH2), 3.2(s,3H,CH2), 4.1(s,1H,CH),
5.3(s,1H,Ar-OH), 6.5-7.0(m,3H,Ar-CH), 8.0(s,1H,NH), 9.2(s,1H,NH).
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Figure 21 shows Mass spectrum of compound IIg
[6-(2-hydroxyethyl)-4-(4-hydroxy-3-methoxyphenyl)-2-thioxo-1,2,3,4,6,7-
hexahydro-5H-pyrrolo[3,4-d]pyrimidin-5-one].
Fig 21 335.4 (M+), 191.3, 120.2, 62.75.
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4.4 PHARMACOLOGICAL EVALUATION40
All the animal experimentation were performed according to the protocol
and the recommendation of the Institutional Animal Ethics Committee.
The following activities were carried out to the synthesized compounds
(i) Acute oral toxicity by acute toxic class method in mice
(ii) Antidepressant activity by Forced swim test in mice
4.4.1. Acute Oral Toxicity Study41
The  test  in  which  a  single  dose  of  the  drug  is  used  in  each  animal  on  one
occasion only for the determination of gross behavior and LD50 or Median lethal
dose. LD50 value is determined in a 24hr test using two species, rodent(mice or rat)
and nonrodent(rabbit).
Acute oral toxicity study was designed as per OECD guidelines 423 for
testing chemicals.
a.  Principle of the test:
The test is based on a stepwise procedure with the use of a minimum number
of  animals  per  step,  sufficient  information  is  obtained  on  the  acute  toxicity  of  the
test substance to enable its classification. The substance is administered orally to a
group of experimental animals at one of the defined doses. The substance is tested
using a stepwise procedure, each step using three animals of a single sex (normally
females). Absence or presence of compound-related mortality of the animals dosed
at one step will determine the next step, i.e.;
? no further testing is needed,
? dosing of three additional animals, with the same dose
? dosing of three additional animals at the next higher or the next lower dose
level.
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b. Experimental protocol (Acute toxic class method)
Toxicity of the synthesized compounds were tested using a stepwise
procedure,  each  step  using  three  mice  of  a  single  sex.  Healthy  young  adult  Swiss
albino mice of weighing 20-25g of single sex were used in the test. The animals
were kept in colony cages at 22°C (±3°C), relative humidity 50-60% under 12hrs
light and 12hrs dark. The dose levels to be used as the starting dose is selected from
one of four fixed levels 5, 50, 300 and 2000mg/kg body weight. Test compounds
administered in the form of suspension in 1% carboxymethylcellulose.
The mice were fasted prior to dosing (food but not water should be withheld
for 3-4hrs). Following the period  of fasting, the animals were weighed and the test
substances were administered orally at  a single  dose of 300mg/kg body weight by
intragastric tube. After the test substances administered, food withheld for further 1-
2hrs.
Animals were observed individually after dosing at least once during the first
30 minutes, periodically during the first 24 hours, with special attention given
during the first 4 hours, and daily thereafter, for a total of 14 days.
As no mortality was observed with the above dose, the next dose 2000mg/kg
body weight administered and the animals were observed for 14 days. Mortality
observed at 2000mg/kg body weight, a series of doses selected below 2000mg/kg
were 250mg/25kg, 500mg/25kg body weight for further pharmacological
evaluation.
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Figure 22 shows the test procedure with a starting dose of 300mg/kg body weight as
per OECD guidelines 423.
Fig 22 starting dose of 300mg/kg body weight.
4.4.2. Evaluation of Antidepressant Activity
Behavioural despair test42,43,44 was  proposed  as  a  model  test  for
antidepressant activity by Porsolt et al. In this method mice or rat forced to swim in
a restricted space from which they cannot escape are induced to a characteristic
behavior of immobility. This behavior reflects a state of despair  which can reduced
by several agents which are therapeutically effective in human depression.
a. Experimental procedure:
Adult albino mice of either sex were used under standard condition with free
access to food and water. The mice were housed in groups of 6 animals for each
cage in a quite and temperature and humidity controlled room in which a 12hrs light
and dark was maintained. On the testing day, mice were assigned into different
groups (n=6 for each groups). The synthesised compounds and fluoxetine as
reference antidepressant drug were suspended in a 1% aqueous solution of
carboxymethyl cellulose. The drugs were given orally in a standard volume of
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0.5ml/20g body weight, 1hr prior to the test. Control animals received 1% aqueous
solution of carboxymethyl cellulose. Then the mice were dropped individually into
the Plexiglass cylinder (25cm height, 30 cm diameter containing water to a height of
20cm at 21-23°C) and left for 6min. After the first 2min of the initial vigorous
struggling the animals were immobile. A mouse was judged immobile if it floated in
water in an upright position and made only slight movements in order to prevent
sinking. The duration of immobility was recorded during the last 4min of the 6min
test.
b. Grouping and drug treatment:
Animals were divided into four groups, each consisting of 6 animals
Group 1 : Control/vehicle treated (1% CMC)
Group 2 : Standard drug fluoxetine 20mg/kg body weight
Group 3(3a-g): Dose 1 (250mg/kg body weight)
Group 4(4a-g): Dose 2 ( 500mg/kg body weight)
The one way ANOVA test was performed using Graph Pad Prism software.
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5. RESULTS AND DISCUSSION
5.1 SYNTHESIS AND CHARACTERIZATION
The target compounds were synthesized by Biginelli reaction followed by
nucleophillic and cyclization reaction. The synthesized compounds were obtained in
good yield and purities. The percentage yield and melting point of synthesized
compounds were recorded.
a.  IR Spectroscopy
The following characteristic stretching vibrations observed from the IR
spectrum of the synthesized compounds.
3425cm-1-3300cm-1 - OH stretching
3200cm-1-3000cm-1 - NH stretching
2970cm-1-2850cm-1 - CH stretching of methylene
1640cm-1-1600cm-1 - C=O stretching of amide
1460cm-1-1430cm-1 - C=C stretching of aromatic
800cm-1-600cm-1 - C-S stretching
These vibrations are indicative of the new functional group that has formed.
Absence of stretching vibrations at 2720cm-1 and 1730cm-1-1720cm-1
indicated that the absence of impurities like aldehydes and ?-ketoester respectively.
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b. 1H NMR Spectroscopy.
The spectral data of the synthesized compounds shown the following peaks.
8-10ppm - singlet was observed due to the presence of NH protons
6.5-7.5ppm - aromatic protons as multiplet
6-7ppm - alcoholic proton appeared as mutiplet
0.3-1.5ppm - multiplet because of the presence of aliphatic protons
c. Mass Spectrometry
All the synthesized compounds were shown their respective molecular peak
and it was observed that the fragment ion peak at m/z value of 63 which is may be
due to the fragment cyclopentadienyl ion.
5.2 PHARMACOLOGICAL EVALUATION
a. Acute toxicity
Acute oral toxicity study was performed according to the OECD guideline
423. The synthesized compounds were suspended in 1% caboxymethyl cellulose
solution and administered in a single dose by intragastric tube to the healthy adult
mice at  starting dose of 2000mg/kg body weight (po). Animal were observed after
dosing for a total of 14days mortality.
No changes in skin and fur, eyes and mucous membrane, autonomic and
central nervous systems, somatomotor activity, tremors, convulsions, salivation,
diarrhea, lethargy, sleep and coma were observed.
Since  sign of toxicity was observed at 2000mg/kg body weight to the group
of animals, the LD50 values of the synthesized compounds(IIa-IIg) expected to be
less than the above dose.
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b. Antidepressant activity
The antidepressant activity of the synthesized compounds were evaluated in
adult Swiss albino mice by Porsolt behavioural despair test. In this method, the mice
were forced to swim in a narrow cylinder from which they cannot escape. Score
immobility during the last 4 min of 6 min session by summing the total time spent
immobile.
The data obtained from antidepressant activity of the synthesized compounds
and reference drug were given in Table 5. It reveal that the compounds IIe and IIg
significantly reduced the duration of immobility at all dose level (250 and 500mg/kg
body  weight)  when  compared  to  control.  Compound  IId  reduce  the  duration  of
immobility at both the dose level. Compounds IIc and IIf were effective at dose of
250mg/kg body weight than 500mg/kg body weight (po). Compounds IIa and IIb
were effective at dose level of 500mg/kg than 250mg/kg body weight (po).
The present study demonstrated that the compounds IIe and IIg were more
active than standard floxetine using despair swim test.
Duration of immobility time in seconds were recorded and given in Table 5.
Table 5. Duration of immobility time
S.No Treatment Groups
Duration of immobility times in seconds
After 1hr
Dose at 250mg/kg Dose at 500mg/kg
1. IIa 87.33 59.17
2. IIb 78.00 65.5
3. IIc 35.50 72.33
4. IId 54.50 55.66
5. IIe 19.17 23.0
6. IIf 20.67 23.6
7. IIg 30.17 44.5
8. Standard 116
9. Control 25.67
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Figure 23 shows the effect of series of synthesized compounds on immobility in sec.
Fig 23 Effects of synthesized compounds on duration of immobility in mice using
forced swim test. Dose 250mg/kg and 500mg/kg body weight were given and
immolity time was recorded after 1 hr.
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Table 6. Effect of synthesized compounds on immobility
S. No
Treatment
groups
Duration of immobility in seconds
(mean± SEM) After 1hr
% Change from control
Dose at
250mg/kg
Dose at
500mg/kg
Dose at
250mg/kg
Dose at
500mg/kg
1. IIa 87.33±5.05 59.17±3.28 -24.71 -48.99
2. IIb 78.0±5.12 65.5±5.65 -32.76 -43.53
3. IIc 35.5±2.06 72.3±3.70 -69.39 -37.64
4. IId 54.5±6.07 55.67±6.32 -53.02 -52.02
5. IIe 19.17±2.63 23.0±2.34 -83.47 -80.17
6. IIf 30.17±2.96 44.5±9.09 -82.18 -77.33
7. IIg 20.67±1.34 26.33±4.47 -73.99 -61.64
8. Standard 116.00±22.75 --
9. Control 25.67±6.25 -74.33
Values are represented as mean ± SEM, (n=6)
Significant when compared to normal control (Dunnet’s test, p?0.05)
All compounds i.e. IIa-IIg showed a significant decrease in duration of
immobility time when compared to control.
Statistical analysis
Results are expressed as mean ± SEM, n represent the number of animals.
Data obtained from pharmacological experiments were analyzed by one way
analysis of variance (ANOVA) followed by Dunnet’s post hoc test. A p-value of
less than 0.05 was considered statistically significant.
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Figure 24 shows the effect of synthesized compounds
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Fig 24 Effects of synthesized compounds on immobility in FST on mice. Compounds
(250mg/kg & 500mg/kg) were injected orally (po) 60 min before the testing, and total
duration of immobility was recorded during the last 5 min of the 6-min testing period.
Values are means ± SEM.
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6. SUMMARY AND CONCLUSION
The present work deals with the synthesis, characterization and
pharmacological evaluation as antidepressant activity of 2-thioxo-5H-pyrrolo[3,4-
d]pyrimidin-5-one derivatives.
The compounds (IIa-IIg) were synthesized by multicomponent reaction
followed by nucleophillic substitution and cyclocondensation reaction. The
synthesized compounds were obtained in good yield.
The melting points of the synthesized compounds were determined and have
been reported uncorrected. Thin layer chromatography was performed on precoated
silicagel G plates using suitable mobile phase.
The synthesized compounds were characterized by IR, Mass and NMR
spectroscopic techniques.
Synthesized compounds were subjected to acute oral toxicity studies. The
LD50 values of the synthesized compounds (IIa-IIg) were expected to be less than
2000mg/kg bodyweight.
All the synthesized compounds were evaluated for their antidepressant activity
by forced swim test in mice. The synthesized compounds IIe and IIg were found to be
more active than standard fluoxetine.
However, neurobiological and basic research as well as clinical studies have
shown that the monoamines have the role in the development of depression
syndrome.
Antidepressant activity is achieved through various mechanism such as
Monoamine oxidase inhibition, Selective serotonin transporter inhibition, inhibition
of Selective serotonin reuptake and norepinephrine reuptake, Dopamine transporter
inhibition, Corticotropin releasing hormone antagonism.
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In this present study it has been identified that the synthesized compounds
possess antidepressant activity but their actual mechanism involved towards
antidepressant activity is unknown. A focused study, in order to identify the actual
mechanism may reveal several facts with respect to antidepressant activity of the
synthesized compounds.
The information and knowledge gained during the course of focused study
may facilitate the process of identifying the ideal antidepressant agent. Hence, an
attempt to study their actual mechanism may be considered in future.
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